Key Developments: Johnson & Johnson (JNJ)

JNJ on New York Consolidated

105.55USD
19 Dec 2014
Price Change (% chg)

$-1.26 (-1.18%)
Prev Close
$106.81
Open
$106.63
Day's High
$107.39
Day's Low
$105.50
Volume
19,144,959
Avg. Vol
8,232,038
52-wk High
$109.49
52-wk Low
$86.09

Search Stocks

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson To Reach $4 Billion Deal On Hip Implant Lawsuits - Reuters
Tuesday, 12 Nov 2013 04:47pm EST 

Reuters reported that Johnson & Johnson will pay more than $4 billion to settle thousands of lawsuits over its recalled defective hip implants. The deal will resolve more than 7,500 lawsuits in federal and state courts by patients who have already had the defective devices removed, the report said.  Full Article

Danaher Corp, Blackstone Group LP Team Up To Bid For Johnson & Johnson's Diagnostics Unit-Reuters
Thursday, 7 Nov 2013 05:33pm EST 

Reuters reported that Danaher Corp has teamed up with Blackstone Group LP to bid for Johnson & Johnson's diagnostics unit, which makes blood screening equipment and laboratory blood tests and could fetch more than $4 billion. Blackstone, declined to comment. Representatives for J&J, Danaher did not immediately respond to requests for comment.  Full Article

Johnson & Johnson To Pay $2.2 Billion To End U.S. Marketing Probes-Reuters
Monday, 4 Nov 2013 10:30am EST 

Reuters reported that Johnson & Johnson will pay $2.2 billion to the U.S. government to end multiple investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses. The settlement with the Company and its subsidiaries covers the marketing of schizophrenia treatment Risperdal and of heart drug Natrecor.  Full Article

FDA Advisory Panel Backs Approval Of Johnson & Johnson's Hepatitis C Drug-Reuters
Thursday, 24 Oct 2013 04:36pm EDT 

Reuters reported that an advisory committee of the U.S. Food and Drug Administration voted unanimously to approve Johnson & Johnson's hepatitis C drug. The panel voted 19-0 in favor of the drug, simeprevir, which was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin. The drug is being developed by J&J unit Janssen Research & Development LLC. It is being tested in adults who failed previous interferon-based therapy or had not received medication at all. The FDA usually follows the recommendation of the advisory panel, although it is not obligated to do so. Hepatitis C, an infection of the liver transmitted through the blood, kills more than 15,000 Americans each year, mostly from hepatitis C-related illnesses such as cirrhosis and liver cancer.  Full Article

Johnson & Johnson's Hepatitis C Drug Gets Positive FDA Review-Reuters
Tuesday, 22 Oct 2013 11:42am EDT 

Reuters reported that a new hepatitis C drug made by Johnson & Johnson showed an acceptable safety profile in clinical trials, reviewers for the U.S. Food and Drug Administration said on October 22, 2013. The drug, simeprevir, was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin, in adult patients who had failed previous interferon-based therapy or had not received medication at all. The safety signal identified in the review of the drug involved rash and/or photosensitivity and the FDA reviewers said they plan to include a related warning in the drug's label. The reviewers said that the drug would be categorized as a Pregnancy Category C in labeling, which means that the potential benefits of the drug may warrant its use in pregnant women, even though animal trials showed the drug had some adverse effects on a fetus.  Full Article

Johnson & Johnson Announces Quarterly Dividend For Fourth Quarter
Thursday, 17 Oct 2013 11:16am EDT 

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2013 of $0.66 per share on the Company's common stock. The dividend is payable on December 10, 2013 to shareholders of record at the close of business on November 26, 2013. The ex-dividend date is November 22, 2013.  Full Article

Johnson & Johnson Raises FY 2013 EPS Guidance
Tuesday, 15 Oct 2013 07:30am EDT 

Johnson & Johnson raised its fiscal 2013 earnings guidance to $5.44-$5.49 per share. The Company's guidance excludes the impact of special items. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $5.46 for fiscal 2013.  Full Article

Johnson & Johnson Receives Private Equity Offers For Diagnostics Unit-Reuters
Monday, 30 Sep 2013 06:22pm EDT 

Reuters reported that some of the world's largest private equity firms have made preliminary offers for Johnson & Johnson's Ortho Clinical Diagnostics unit, which makes blood screening equipment and laboratory blood tests and could fetch around $5 billion, several people familiar with the matter said on Monday. Blackstone Group LP, KKR & Co LP, Bain Capital LLC, Carlyle Group LP and BC Partners Ltd are among the buyout firms that submitted first-round bids last week and are waiting to hear back this week on who made the shortlist, the sources said.  Full Article

Johnson & Johnson Recalls Some Batches Of Antipsychotic Drug Over Mold Concerns-DJ
Wednesday, 11 Sep 2013 05:49pm EDT 

Dow Jones reported that Johnson & Johnson (JNJ) recalled another product on Wednesday, pulling some vials of its antipsychotic treatment Risperdal Consta after discovering mold during routine quality testing. The New Brunswick, N.J., health-products maker estimates that 5,000 of the 70,000 vials made in a single lot last year remain unused in doctor's offices, community mental health centers and pharmacies and must be withdrawn. Because it is injected, Risperdal Consta is stored and given at the clinics, rather than the patients keeping and taking the drug themselves. J&J, which announced the recall in a letter to doctors and on company Websites, said the Alternaria alternata mold that was discovered is found commonly in the environment and could cause infections around the area where the injection is given. The Risperdal Consta that was recalled was the 25mg dose. It was made by another company, Alkermes PLC (ALKS), and shipped from Jan. 14 to May 20, 2013, according to J&J.  Full Article

Johnson & Johnson Unit Issues U.S. Recall Of Motrin Drops For Infants-Reuters
Sunday, 8 Sep 2013 05:39pm EDT 

Reuters reported that Johnson & Johnson consumer healthcare unit said, it is recalling about 200,000 bottles of concentrated Motrin drops for infants due to potential contamination with plastic particles. Three lots are being recalled because plastic particles, about the size of a poppy seed, were identified during the manufacturing of a fourth, undistributed, lot of the drops.  Full Article

Galapagos loses partner on inflammatory bowel drug

BRUSSELS - Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease.

Search Stocks